Dhanuka Agritech Ltd
DHANUKADhanuka Agritech Ltd is cheap for a reason. The P/E sits at the 15th percentile of its own range, and the quarters are still getting worse.
The sharpest disagreement: annual EPS moved +25.6% against a −37.9% price move — the market has not yet caught up with the delivery.
The price is in a downtrend (40 weeks in) while the P/E sits at the 15th percentile of its own 11-year range. Underneath, the last four quarters read deteriorating — profit −27.3% year on year, and 69% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Dhanuka Agritech Ltd trades at ₹1,022, in a downtrend and 40 weeks into that stage. That is −10.7% against its own 200-day average. It sits at 15% of a 52-week range of ₹936 to ₹1,527. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (9 weeks and counting).
Today the stock is in a downtrend — week 40 of stage 4, confirmed. At ₹1,022 it trades −10.7% versus its 200-day average and sits at 15% of its 52-week range (₹936–₹1,527).
Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved +84% while the NIFTY 500 moved +274% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (9 weeks and counting; last ahead the week of 2026-06-17) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Dhanuka Agritech Ltd trades at 15.6× P/E, near the bottom of its own range — cheaper only 15% of the time. Its long-run median P/E is 19.2×, measured across 10.5 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 15.6× is near the bottom of its own range — cheaper only 15% of the time, against a long-run median of 19.2× measured over 10.5 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
One caveat before moving on: margins are the best this company has ever printed — cheap against its own history on record margins is not the same thing as cheap. If profitability mean-reverts, today's multiple is higher than it looks.
Why the multiple sits where it does: over the past year annual EPS moved +25.6% against a −37.9% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the +1.5%/yr price move, ~+7.9%/yr came from earnings growth and ~−6.4 pp from the multiple (compressing); over 10y, of the +4.4%/yr price move, ~+11.6%/yr came from earnings growth and ~−7.2 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Topping out Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Dhanuka Agritech Ltd reads as topping out on its fundamental arc. Topping out — revenue, profit and EPS growth have decelerated hard (revenue growth +15.0% at its peak → +0.9% latest) while ROCE still reads 24.6%. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: decelerating from a peak is where good stories quietly end — the multiple usually notices late.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +15.7% | +11.2% | +12.7% | +10.0% |
| Profit | +24.3% | +12.4% | +16.1% | +10.9% |
| EPS | +25.6% | +13.7% | +17.3% | +12.0% |
| Share price | −37.9% | +10.8% | +1.5% | +4.4% |
4-Factor Sector Score
46.6/100 — rank 13 of 24 in Pesticides/Agrochemicals · 96% evidence confidence
Dhanuka Agritech Ltd scores 46.6 out of 100 against the 24 companies it is compared with in Pesticides/Agrochemicals, ranking 13. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 8.3 + 19.1 + 13 + 6.2 = 46.6. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Dhanuka Agritech Ltd reported ₹410 Cr of revenue in the Dec 25 quarter, −7.9% year on year. Over 10 years it has compounded at 10.0% a year. The last full year, FY25, came in at ₹2,035 Cr. The last four reported quarters add to ₹1,978 Cr.
FY25 revenue came in at ₹2,035 Cr (+15.7% on the year), capping 10 years at 10.0% compound. The latest quarter (Dec 25) printed ₹410 Cr, −7.9% year on year.
Pace check: the last four quarters averaged +2.6% growth against the decade's 10.0% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +0.9% over the last 4 quarters against +6.0%/yr over the last 8 — rolling over; TTM profit −5.3% vs +4.2%/yr — rolling over.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Dhanuka Agritech Ltd's operating margin is 14.0% in the Dec 25 quarter, −3.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 12 fiscal years the operating margin has ranged 15.0% to 20.0%. The current quarter is running below every full year in that window.
The latest quarter's operating margin is 14.0%, −3.0 pp against the same quarter a year ago. Across 12 fiscal years the operating margin has ranged 15.0%–20.0%, and FY25's 20.0% is the top of that band — a record year.
Why the margin moved: operating margin went +3.1 pp year on year while gross margin went −0.4 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Dhanuka Agritech Ltd earned ₹40.0 Cr of net profit in the Dec 25 quarter, −27.3% year on year. Full-year FY25 profit was ₹297 Cr. The 10-year compound rate is 10.9%. That is 9.8% of the quarter's revenue. The same quarter a year earlier earned ₹55.0 Cr.
Dec 25 profit was ₹40.0 Cr, −27.3% year on year. On the full year, FY25 printed ₹297 Cr (+24.3%), and the 10-year compound rate is 10.9%.
🚨 Why profit moved: revenue contributed −7.9% and the margin −3.0 pp — the quarter was revenue-led despite a thinner margin.
Pace comparison, last four quarters: profit −1.1% vs revenue +2.6%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 69% of Dhanuka Agritech Ltd's reported profit arrived as operating cash — most of the profit is real cash. In FY25 that was ₹263 Cr of operating cash against ₹297 Cr of profit. After ₹202 Cr of capital spending, ₹61.0 Cr was left as free cash.
FY25: operating cash of ₹263 Cr against reported profit of ₹297 Cr, leaving free cash of ₹61.0 Cr after ₹202 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 69% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why conversion sits at 69%: the cash cycle stretched 12 days between FY20 and FY25 — more of each rupee of profit waits inside the cycle before arriving. Less than 70% of profit arriving as cash is the thing to watch on this page.
Router verdict: conversion is below par and the cash cycle has stretched 12 days — the next section's job is to find where the cash is stuck.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Dhanuka Agritech Ltd's cash conversion cycle runs 168 days in FY25, up from 156 days in FY20. Capital spending ran ₹420 Cr over the last 3 years. At FY25 sales of ₹2,035 Cr each day of that cycle holds about ₹5.6 Cr, so roughly ₹937 Cr sits inside the business at any moment.
FY25: debtors at 82 days, inventory at 132 days — roughly 4.3 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 168 days, looser than FY20's 156.
The full loop: cash goes out to suppliers and production on day 0; stock waits 132 days to sell; customers pay about 82 days after that; and suppliers themselves are paid at 46 days — netting out to the 168-day cycle.
In money terms: at FY25 sales of ₹2,035 Cr, each day of the cycle holds about ₹5.6 Cr — so the 168-day loop keeps roughly ₹937 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹420 Cr over the last 3 fiscal years against ₹114 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹9.0 Cr (FY25) — capacity paid for but not yet earning.
The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Dhanuka Agritech Ltd earns a ROCE of 28% in FY25. That is up from a trough of 23% in FY19. Return on invested capital clears the cost of that capital by +4.8 percentage points, so growth here adds value rather than only size. The wiring behind it is 14.6% net margin on 1.13× asset turns.
FY25 ROCE is 28%, recovered from a FY19 trough of 23% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY25): 14.6% net margin × 1.13× asset turns × 1.28× balance-sheet leverage ≈ 21.1% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 16.8% − 12.0% = a +4.8 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Dhanuka Agritech Ltd carries total debt of ₹31.0 Cr against shareholder equity of ₹1,682 Cr as of Mar 26, a debt-to-equity of 0.02 — effectively unlevered. On the annual view that ratio went from 0.03 in FY22 to 0.02 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹31.0 Cr against shareholder equity of ₹1,682 Cr — a debt-to-equity of 0.02. On the annual view, debt-to-equity went from 0.03 (FY22) to 0.02 (FY26). The returns on this page are earned, not borrowed.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of Dhanuka Agritech Ltd moved a full percentage point over the last two years — the register is quiet. Promoters moved −0.4 points over the same window, to 69.8%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: −0.6 points over 8 quarters to 18.7%; Promoters: −0.4 points over 8 quarters to 69.8%; Foreign institutions: +0.1 points over 8 quarters to 1.6%.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Dhanuka Agritech Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Titan Biotech Ltd524717 | 69.3/100Favorable setup78% evidence | ASLEEP | 29.1/35 Revenue 31.8% · PAT 38.7% · OPM change 6.9 pp 83% evidence | 20.2/25 ROCE 22.8% · OPM 19.9% 76% evidence | 6.0/20 P/E 57.8× · PEG — 50% evidence | 14.0/20 RS sector 41.7% · RS bench 39.3% · 1Y 371.1%5 of 12 weeks ahead 100% evidence |
| Exact sum: 29.1 + 20.2 + 6 + 14 = 69.3 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Sharda Cropchem LtdSHARDACROP | 65.3/100Favorable setup97% evidence | ASLEEP | 23.7/35 Revenue 18.5% · PAT 49% · OPM change -5 pp 95% evidence | 18.5/25 ROCE 30.2% · OPM 17% 95% evidence | 19.2/20 P/E 11.8× · PEG 0.26 100% evidence | 3.9/20 RS sector -10.9% · RS bench -13.7% · 1Y -24.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 23.7 + 18.5 + 19.2 + 3.9 = 65.3 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -10.9% and the one-year return is -24.6%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 3Punjab Chemicals & Crop Protection LtdPUNJABCHEM | 61.8/100Mixed-positive evidence81% evidence | ASLEEP | 22.7/35 Revenue 8.2% · PAT 43.5% · OPM change 1 pp 95% evidence | 18.3/25 ROCE 18.6% · OPM 12% 95% evidence | 12.1/20 P/E 21× · PEG — 50% evidence | 8.7/20 RS sector -6.2% · RS bench -2.6% · 1Y -13.2%1 of 10 weeks ahead 70% evidence |
| Exact sum: 22.7 + 18.3 + 12.1 + 8.7 = 61.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Bayer CropScience LtdBAYERCROP | 61.7/100Mixed-positive evidence70% evidence | ASLEEP | 21.4/35 Revenue 3.7% · PAT 21.7% · OPM change 2.1 pp 83% evidence | 19.1/25 ROCE 20.1% · OPM 18.4% 95% evidence | 8.5/20 P/E 387× · PEG — 15% evidence | 12.7/20 RS sector 9.4% · RS bench -10.7% · 1Y -33.2%0 of 10 weeks ahead 70% evidence |
| Exact sum: 21.4 + 19.1 + 8.5 + 12.7 = 61.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Dharmaj Crop Guard LtdDHARMAJ | 61.1/100Mixed-positive evidence62% evidence | TURNING | 23.8/35 Revenue 19.6% · PAT 56.9% · OPM change 2.7 pp 62% evidence | 12.9/25 ROCE 16.4% · OPM 4.5% 95% evidence | 10.6/20 P/E 16.6× · PEG — 15% evidence | 13.8/20 RS sector 5% · RS bench -2.5% · 1Y -13.2%4 of 10 weeks ahead 70% evidence |
| Exact sum: 23.8 + 12.9 + 10.6 + 13.8 = 61.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Advance Agrolife LtdADVANCE | 56.3/100Thin evidence · provisional56% evidence | TURNING | 21.4/35 Revenue 27% · PAT 37.6% · OPM change 4.3 pp 83% evidence | 14.8/25 ROCE 19.3% · OPM 10.8% 95% evidence | 10.1/20 P/E 22.8× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —2 of 10 weeks ahead 0% evidence |
| Exact sum: 21.4 + 14.8 + 10.1 + 10 = 56.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 7UPL LtdUPL | 54.2/100Mixed-positive evidence90% evidence | ASLEEP | 20.6/35 Revenue 11.2% · PAT 100% · OPM change -1 pp 88% evidence | 9.3/25 ROCE 10.1% · OPM 19% 100% evidence | 12.5/20 P/E 28.3× · PEG 0.5 100% evidence | 11.8/20 RS sector 4.9% · RS bench -12.2% · 1Y -16.3%0 of 10 weeks ahead 70% evidence |
| Exact sum: 20.6 + 9.3 + 12.5 + 11.8 = 54.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8India Pesticides LtdIPL | 54.0/100Mixed-positive evidence81% evidence | TURNING | 20.0/35 Revenue 17% · PAT 10.1% · OPM change -2 pp 95% evidence | 13.6/25 ROCE 16.7% · OPM 14% 95% evidence | 14.1/20 P/E 16.5× · PEG — 50% evidence | 6.3/20 RS sector -11.9% · RS bench -12.1% · 1Y -27.3%4 of 11 weeks ahead 70% evidence |
| Exact sum: 20 + 13.6 + 14.1 + 6.3 = 54 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Jubilant Ingrevia LtdJUBLINGREA | 52.7/100Mixed-positive evidence93% evidence | FADING | 18.2/35 Revenue 11% · PAT 11.2% · OPM change 1 pp 100% evidence | 10.2/25 ROCE 11.4% · OPM 15% 100% evidence | 6.4/20 P/E 36.8× · PEG 2.37 65% evidence | 17.9/20 RS sector 11.8% · RS bench 7.8% · 1Y -5.6%6 of 12 weeks ahead 100% evidence |
| Exact sum: 18.2 + 10.2 + 6.4 + 17.9 = 52.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Bharat Rasayan LtdBHARATRAS | 51.6/100Mixed-positive evidence77% evidence | ASLEEP | 17.1/35 Revenue 5.8% · PAT 3.5% · OPM change 4 pp 83% evidence | 16.5/25 ROCE 17.4% · OPM 16% 95% evidence | 14.7/20 P/E 13.3× · PEG — 50% evidence | 3.3/20 RS sector -33.2% · RS bench -34.6% · 1Y -51.5%0 of 11 weeks ahead 70% evidence |
| Exact sum: 17.1 + 16.5 + 14.7 + 3.3 = 51.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Bhagiradha Chemicals & Industries LtdBHAGCHEM | 51.0/100Mixed-positive evidence88% evidence | TURNING | 23.6/35 Revenue 21.7% · PAT 31.1% · OPM change 7.3 pp 65% evidence | 5.8/25 ROCE 4.5% · OPM 12.3% 100% evidence | 2.0/20 P/E 207× · PEG 3.04 100% evidence | 19.6/20 RS sector 22.5% · RS bench 17.9% · 1Y -0.7%11 of 12 weeks ahead 100% evidence |
| Exact sum: 23.6 + 5.8 + 2 + 19.6 = 51 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12GSP Crop Science LtdGSPCROP | 50.4/100Thin evidence · provisional59% evidence | TURNING | 16.5/35 Revenue 21.2% · PAT 37.8% · OPM change -4 pp 88% evidence | 14.3/25 ROCE 19% · OPM 9% 100% evidence | 9.6/20 P/E 26.8× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —3 of 3 weeks ahead 0% evidence |
| Exact sum: 16.5 + 14.3 + 9.6 + 10 = 50.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 13Dhanuka Agritech Ltdthis pageDHANUKA | 46.6/100Mixed-negative evidence96% evidence | ASLEEP | 8.3/35 Revenue 0.9% · PAT -5.3% · OPM change -2.5 pp 88% evidence | 19.1/25 ROCE 28.3% · OPM 22.5% 100% evidence | 13.0/20 P/E 15.6× · PEG 1.72 100% evidence | 6.2/20 RS sector -12.4% · RS bench -16.2% · 1Y -40.9%4 of 12 weeks ahead 100% evidence |
| Exact sum: 8.3 + 19.1 + 13 + 6.2 = 46.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Sumitomo Chemical India LtdSUMICHEM | 45.4/100Mixed-negative evidence94% evidence | TURNING | 12.1/35 Revenue -3.6% · PAT 3.9% · OPM change 1 pp 100% evidence | 19.0/25 ROCE 22.1% · OPM 22% 100% evidence | 4.0/20 P/E 44.6× · PEG 4 100% evidence | 10.3/20 RS sector -8.2% · RS bench 6% · 1Y -12.8%9 of 10 weeks ahead 70% evidence |
| Exact sum: 12.1 + 19 + 4 + 10.3 = 45.4 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 15Rallis India LtdRALLIS | 45.3/100Mixed-negative evidence91% evidence | ASLEEP | 16.1/35 Revenue 7.3% · PAT -28.4% · OPM change 2.6 pp 95% evidence | 9.3/25 ROCE 12.8% · OPM 15.2% 95% evidence | 11.4/20 P/E 26.7× · PEG 0.89 100% evidence | 8.5/20 RS sector -1.8% · RS bench -20.7% · 1Y -39.2%0 of 10 weeks ahead 70% evidence |
| Exact sum: 16.1 + 9.3 + 11.4 + 8.5 = 45.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16NACL Industries LtdNACLIND | 44.9/100Mixed-negative evidence94% evidence | TURNING | 28.1/35 Revenue 11.9% · PAT 100% · OPM change 3 pp 100% evidence | 4.4/25 ROCE 8.1% · OPM 11% 100% evidence | 3.8/20 P/E 171× · PEG 2.02 100% evidence | 8.6/20 RS sector -12.5% · RS bench 3.8% · 1Y -26.9%10 of 10 weeks ahead 70% evidence |
| Exact sum: 28.1 + 4.4 + 3.8 + 8.6 = 44.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Astec Lifesciences LtdASTEC | 44.9/100Mixed-negative evidence63% evidence | ASLEEP | 23.3/35 Revenue 9.4% · PAT 47.7% · OPM change 11.2 pp 71% evidence | 2.6/25 ROCE -5.4% · OPM -0.8% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 9.0/20 RS sector -3.5% · RS bench -9.3% · 1Y -27.2%7 of 10 weeks ahead 70% evidence |
| Exact sum: 23.3 + 2.6 + 10 + 9 = 44.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Meghmani Organics LtdMOL | 44.3/100Mixed-negative evidence74% evidence | TURNING | 20.6/35 Revenue -7.8% · PAT 100% · OPM change 7 pp 95% evidence | 9.4/25 ROCE 6.7% · OPM 18% 95% evidence | 10.2/20 P/E 21.3× · PEG — 15% evidence | 4.1/20 RS sector -33.7% · RS bench -13.6% · 1Y -42.8%3 of 10 weeks ahead 70% evidence |
| Exact sum: 20.6 + 9.4 + 10.2 + 4.1 = 44.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Insecticides India LtdINSECTICID | 43.8/100Mixed-negative evidence77% evidence | ASLEEP | 11.9/35 Revenue 7% · PAT -1.4% · OPM change -2 pp 83% evidence | 13.0/25 ROCE 15.8% · OPM 6% 95% evidence | 11.7/20 P/E 13.5× · PEG — 50% evidence | 7.2/20 RS sector -8.5% · RS bench -9.5% · 1Y -38.7%7 of 10 weeks ahead 70% evidence |
| Exact sum: 11.9 + 13 + 11.7 + 7.2 = 43.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Excel Industries LtdEXCELINDUS | 43.1/100Mixed-negative evidence70% evidence | TURNING | 14.4/35 Revenue 12% · PAT -11.8% · OPM change 0 pp 83% evidence | 8.6/25 ROCE 6.1% · OPM 8% 95% evidence | 10.9/20 P/E 16.4× · PEG — 15% evidence | 9.2/20 RS sector -4.6% · RS bench -2.6% · 1Y -27.3%2 of 10 weeks ahead 70% evidence |
| Exact sum: 14.4 + 8.6 + 10.9 + 9.2 = 43.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21Epigral LtdEPIGRAL | 41.3/100Mixed-negative evidence94% evidence | ASLEEP | 6.5/35 Revenue 4.8% · PAT -37.4% · OPM change -2 pp 100% evidence | 14.3/25 ROCE 15.5% · OPM 25% 100% evidence | 16.5/20 P/E 17.3× · PEG 0.43 100% evidence | 4.0/20 RS sector -32.9% · RS bench -17.5% · 1Y -40.9%7 of 10 weeks ahead 70% evidence |
| Exact sum: 6.5 + 14.3 + 16.5 + 4 = 41.3 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 22P I Industries LtdPIIND | 40.9/100Mixed-negative evidence90% evidence | ASLEEP | 6.6/35 Revenue -15.9% · PAT -20.5% · OPM change -3 pp 88% evidence | 15.5/25 ROCE 15% · OPM 22% 100% evidence | 10.6/20 P/E 34.7× · PEG 1.71 100% evidence | 8.2/20 RS sector -3.4% · RS bench -15.3% · 1Y -32.8%0 of 10 weeks ahead 70% evidence |
| Exact sum: 6.6 + 15.5 + 10.6 + 8.2 = 40.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Best Agrolife LtdBESTAGRO | 29.7/100Adverse evidence81% evidence | TURNING | 7.9/35 Revenue -24.1% · PAT -56.5% · OPM change 8 pp 95% evidence | 9.0/25 ROCE 5.2% · OPM 20% 95% evidence | 7.0/20 P/E 22.9× · PEG — 50% evidence | 5.8/20 RS sector -30.7% · RS bench -8.5% · 1Y -36.9%1 of 11 weeks ahead 70% evidence |
| Exact sum: 7.9 + 9 + 7 + 5.8 = 29.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Heranba Industries LtdHERANBA | 25.7/100Adverse evidence65% evidence | ASLEEP | 11.7/35 Revenue 13.1% · PAT -80% · OPM change -2.7 pp 62% evidence | 1.2/25 ROCE -1.6% · OPM -7% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 2.8/20 RS sector -22% · RS bench -25.7% · 1Y -51.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 11.7 + 1.2 + 10 + 2.8 = 25.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Dhanuka Agritech Ltd's share price today?
Dhanuka Agritech Ltd trades at ₹1,022, −37.9% over the past year. The company is valued at ₹4,555 Cr. The stock sits at 15% of its 52-week range of ₹936–₹1,527, −10.7% versus its 200-day average. On the tape, the price is in a downtrend, 40 weeks in. — as of 31 July 2026.
What were Dhanuka Agritech Ltd's latest quarterly results?
Dhanuka Agritech Ltd reported revenue of ₹410 Cr and net profit of ₹40.0 Cr for the Dec 25 quarter. Revenue fell 7.9% and profit fell 27.3% year on year. Earnings per share were ₹8.87. The operating margin was 14.0%, 3.0 pp lower than a year earlier. — as of 31 July 2026.
What is Dhanuka Agritech Ltd's revenue?
Dhanuka Agritech Ltd reported revenue of ₹410 Cr in the Dec 25 quarter, −7.9% year on year. For the full FY25 fiscal year, revenue was ₹2,035 Cr (+15.7%). Over the last 10 years revenue compounded at 10.0% a year. — as of 31 July 2026.
What is Dhanuka Agritech Ltd's profit?
Dhanuka Agritech Ltd earned ₹40.0 Cr of net profit in the Dec 25 quarter, −27.3% year on year. Full-year FY25 profit was ₹297 Cr. The operating margin ran 14.0% in the latest quarter. — as of 31 July 2026.
What is Dhanuka Agritech Ltd's market cap?
Dhanuka Agritech Ltd's market capitalisation is ₹4,555 Cr at a share price of ₹1,022. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is Dhanuka Agritech Ltd's P/E ratio?
Dhanuka Agritech Ltd trades at a P/E of 15.6×, at the 15th percentile of its own 11-year range, against a long-run median of 19.2×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does Dhanuka Agritech Ltd pay a dividend?
Yes — Dhanuka Agritech Ltd's dividend payout was 3% of profit in FY25, and it recorded a payout in each of its last 12 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 31 July 2026.
Is Dhanuka Agritech Ltd overvalued?
On its own history, Dhanuka Agritech Ltd looks cheap against its own history: its P/E of 15.6× has been cheaper only 15% of the time in 11 years (long-run median 19.2×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 31 July 2026.
Is Dhanuka Agritech Ltd growing?
Not right now — Dhanuka Agritech Ltd's latest numbers are shrinking: latest-quarter revenue −7.9% year on year, profit −27.3%, and the margin −3.0 pp at 14.0%. The 10-year compound rates are 10.0% (revenue) and 10.9% (profit). The earnings engine currently reads: deteriorating — as of 31 July 2026.
How is Dhanuka Agritech Ltd performing?
Dhanuka Agritech Ltd is in a downtrend, 40 weeks in. Its latest quarter's revenue fell 7.9% and profit fell 27.3% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 9 weeks. This describes what the data did, not a rating. — as of 31 July 2026.
What stage is Dhanuka Agritech Ltd in?
Topping out — revenue, profit and EPS growth have decelerated hard (revenue growth +15.0% at its peak → +0.9% latest) while ROCE still reads 24.6%. The read comes from the last 12 quarters of growth (revenue growth +0.9% latest, profit growth −5.3% latest, eps growth −5.1% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 31 July 2026.
Is Dhanuka Agritech Ltd in an uptrend?
No — the price is in a downtrend (week 40 of stage 4), trading −10.7% versus its 200-day average and at 15% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is Dhanuka Agritech Ltd beating the market?
Not lately — on a trailing-13-week view Dhanuka Agritech Ltd is currently behind the NIFTY 500 (9 weeks and counting; last ahead the week of 2026-06-17), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.4 years the stock moved +84% against the NIFTY 500's +274% — behind the index over the full window. — as of 31 July 2026.
Will Dhanuka Agritech Ltd's share price go up?
This page publishes no price forecast for Dhanuka Agritech Ltd. What it measures instead: the share price is ₹1,022, the price is in a downtrend 40 weeks in. Its P/E of 15.6× sits at the 15th percentile of its own 11-year range. — as of 31 July 2026.
Who owns Dhanuka Agritech Ltd?
Promoters hold 69.8% of Dhanuka Agritech Ltd, foreign institutions 1.6%, domestic institutions 18.7% and the public 9.8% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 31 July 2026.
Does Dhanuka Agritech Ltd have too much debt?
No — Dhanuka Agritech Ltd's debt-to-equity is 0.05, and operating profit covers the interest bill 83×. FY25 borrowings were ₹74.0 Cr against equity of ₹1,403 Cr. The returns on this page are earned, not borrowed — as of 31 July 2026.
What is Dhanuka Agritech Ltd's capex?
Dhanuka Agritech Ltd spent ₹420 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was ₹202 Cr, with ₹9.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is Dhanuka Agritech Ltd's cash flow?
Dhanuka Agritech Ltd generated ₹263 Cr of operating cash flow in FY25 and ₹61.0 Cr of free cash flow after ₹202 Cr of capital spending. Reported profit that year was ₹297 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is Dhanuka Agritech Ltd's profit real cash?
Mostly — over the last 3 fiscal years, 69% of Dhanuka Agritech Ltd's reported profit arrived as operating cash. In FY25, operating cash was ₹263 Cr against reported profit of ₹297 Cr. The cash then goes mostly into the working-capital cycle. Cash-flow resolution is annual — as of 31 July 2026.
Where is Dhanuka Agritech Ltd in its business cycle?
Dhanuka Agritech Ltd's FY25 operating margin was 20.0%, against a 12-year band of 15.0%–20.0%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 14.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the Dhanuka Agritech Ltd story?
The sharpest disagreement: annual EPS moved +25.6% against a −37.9% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is Dhanuka Agritech Ltd a stock worth studying right now?
This is not investment advice. The machine read: Dhanuka Agritech Ltd is cheap for a reason. The P/E sits at the 15th percentile of its own range, and the quarters are still getting worse. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.